Cargando…

Improved homology modeling of the human & rat EP(4) prostanoid receptors

BACKGROUND: The EP(4) prostanoid receptor is one of four GPCRs that mediate the diverse actions of prostaglandin E(2) (PGE(2)). Novel selective EP(4) receptor agonists would assist to further elucidate receptor sub-type function and promote development of therapeutics for bone healing, heart failure...

Descripción completa

Detalles Bibliográficos
Autores principales: Holt, Melissa C., Ho, Chi S., Morano, M. Inés, Barrett, Stephen D., Stein, Adam J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712885/
https://www.ncbi.nlm.nih.gov/pubmed/31455205
http://dx.doi.org/10.1186/s12860-019-0212-5
Descripción
Sumario:BACKGROUND: The EP(4) prostanoid receptor is one of four GPCRs that mediate the diverse actions of prostaglandin E(2) (PGE(2)). Novel selective EP(4) receptor agonists would assist to further elucidate receptor sub-type function and promote development of therapeutics for bone healing, heart failure, and other receptor associated conditions. The rat EP(4) (rEP(4)) receptor has been used as a surrogate for the human EP(4) (hEP(4)) receptor in multiple SAR studies. To better understand the validity of this traditional approach, homology models were generated by threading for both receptors using the RaptorX server. These models were fit to an implicit membrane using the PPM server and OPM database with refinement of intra and extracellular loops by Prime (Schrödinger). To understand the interaction between the receptors and known agonists, induced-fit docking experiments were performed using Glide and Prime (Schrödinger), with both endogenous agonists and receptor sub-type selective, small-molecule agonists. The docking scores and observed interactions were compared with radioligand displacement experiments and receptor (rat & human) activation assays monitoring cAMP. RESULTS: Rank-ordering of in silico compound docking scores aligned well with in vitro activity assay EC(50) and radioligand binding K(i). We observed variations between rat and human EP(4) binding pockets that have implications in future small-molecule receptor-modulator design and SAR, specifically a S103G mutation within the rEP4 receptor. Additionally, these models helped identify key interactions between the EP(4) receptor and ligands including PGE(2) and several known sub-type selective agonists while serving as a marked improvement over the previously reported models. CONCLUSIONS: This work has generated a set of novel homology models of the rEP(4) and hEP(4) receptors. The homology models provide an improvement upon the previously reported model, largely due to improved solvation. The hEP(4) docking scores correlates best with the cAMP activation data, where both data sets rank order Rivenprost>CAY10684 > PGE(1) ≈ PGE(2) > 11-deoxy-PGE(1) ≈ 11-dexoy-PGE(2) > 8-aza-11-deoxy-PGE(1). This rank-ordering matches closely with the rEP(4) receptor as well. Species-specific differences were noted for the weak agonists Sulprostone and Misoprostol, which appear to dock more readily within human receptor versus rat receptor. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12860-019-0212-5) contains supplementary material, which is available to authorized users.